Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Arcoxia

- PMLiVE

CHMP backs MSD’s CMV infection treatment

Prevymis is set to be available as an injectable and tablets

- PMLiVE

Merck pulls Keytruda filing in Europe, despite US approval

Phase II KeyNote-0241 trial results failed to win over the EMA

- PMLiVE

MSD touts Keytruda first-line promise in NSCLC

Says patients on the drug more than doubled median OS compared to chemo

- PMLiVE

Pursuing better outcomes for people with pain

Using the patient’s voice to change how we conduct R&D

- PMLiVE

MSD’s Keytruda wins new bladder cancer indication in Europe

Will treat locally advanced or mUC patients

- PMLiVE

Merck CEO resigns from Trump post in Charlottesville protest

Frazier leaves the Manufacturing Council but J&J’s Gorksy remains for now

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Merck suspends two Keytruda trials after patient deaths

Investigators to look at Keytruda with Pomalyst and Revlimid

AstraZeneca AZ

Grünenthal buys Zomig rights as AZ slimming drive continues

Acquires global rights outside Japan to the migraine drug

- PMLiVE

MSD probed by UK for blocking Remicade biosimilars

Pharma giant’s discount scheme for infliximab labelled ‘anti-competitive’

- PMLiVE

Grünenthal’s relentless pursuit of relief

New CEO Gabriel Baertschi on putting pain in the crosshairs of innovation

- PMLiVE

NICE turns down first-line Keytruda for lung cancer

High cost of drug puts it above cost-effectiveness threshold

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links